Candel Therapeutics Inc. Financials
CADL
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 ~1.7:1 split | DEC 2024 | DEC 2023 | DEC 2022 ~1.5:1 split | DEC 2021 ~1.6:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | – | – | – | $0 | $0 |
| General & Administrative | $14 | $18 | $14 | $14 | $14 | $11 |
| Research & Development | $21 | $30 | $19 | $25 | $21 | $15 |
| Total Operating Expenses | $35 | $48 | $33 | $38 | $35 | $26 |
| Operating Income | -$35 | -$48 | -$33 | -$38 | -$35 | -$26 |
| Non-Operating | ||||||
| Net Interest Expense | $1 | -$2 | -$2 | -$1 | -$0 | -$0 |
| Other Non-Operating Income (Expense) | $16 | $12 | -$20 | $0 | $16 | -$10 |
| EBT (Earnings Before Tax) | – | -$38 | -$55 | – | – | – |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ||||||
| Net Income | -$19 | -$38 | -$55 | -$38 | -$19 | -$36 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | – | – | – | $0.00 | $0.01 |
| EPS (Basic) | -$0.65 | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 |
| EPS (Diluted) | -$0.65 | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 |
| Weighted Avg Shares (Basic) | 28.8M | 53.0M | 31.7M | 28.9M | 28.8M | 18.9M |
| Weighted Avg Shares (Diluted) | 28.8M | 53.0M | 31.7M | 28.9M | 28.8M | 18.9M |
| Shares Outstanding | 28.8M | 53.0M | 31.7M | 28.9M | 28.8M | 18.9M |
Candel Therapeutics (CADL) financials: revenue, profit and margins
Candel Therapeutics (CADL) generated about n/a in revenue and -$99 million in net income over the trailing twelve months, growing at roughly 0.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Candel Therapeutics profitable?+
Candel Therapeutics reported about -$99 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Candel Therapeutics growing?+
Candel Therapeutics's revenue has compounded at roughly 0.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside CADL's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 5 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CADL
Held by ETFs
CADL is in 16 US ETFs. The largest of them, with CADL's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.18%of the fund
iShares Biotechnology ETFIBB0.04%of the fund
State Street SPDR S&P Kensho New Economies Composite ETFKOMP0.09%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.04%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.04%of the fund
Spot a number that looks wrong? Check it in CADL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CADL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.